On October 8, 2026 Alpha-9 Oncology Inc. ("Alpha-9"), a clinical-stage radiotherapeutic company developing targeted, next-generation treatments to meaningfully improve the lives of those living with cancer, reported an upcoming oral presentation supporting the use of 68Ga-A9-6217 PET/CT imaging in patients with gastrin-releasing peptide receptor ("GRPR") expressing tumors at the European Association of Nuclear Medicine 2026 Annual Congress, taking place in Vienna, Austria, from October 17-21, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Alpha-9 is currently enrolling a Phase 1 clinical trial evaluating safety, tolerability, and recommended dose for expansion of 225Ac-A9-0642 and 177Lu-A9-0631 in patients with GRPR-positive solid tumors, including locally advanced, unresectable or metastatic HR+/HER2- breast cancer and other solid tumors. Alpha-9 is currently using its GRPR imaging agent, 68Ga-A9-6217, for patient selection.
Oral Presentation Details:
Title: A Phase 1 Study Investigating the Safety, Biodistribution, and Dosimetry of [68Ga]Ga-A9-6217 in Participants with Select Advanced or Metastatic Solid Tumors: Case series of selected patients
Presentation Number: OP-877
Date/Time: Wednesday, October 21, 2026, 9:45 – 11:15 AM CEST, Hall C
Full abstracts are available online in the EANM’26 Abstract Book.
(Press release, Alpha9 Oncology, OCT 8, 2026, View Source [SID1234673279])